MedPath

Tagged News

BriaCell Secures New Zealand Patent for HLA-Matched Whole-Cell Cancer Immunotherapy Technology

Precision Medicine
  • BriaCell Therapeutics has been granted New Zealand Patent No. 785587 for its whole-cell cancer vaccine technology, providing exclusivity through February 27, 2037.
  • The patent covers methods for selecting whole-cell cancer immunotherapy based on HLA allele profile matching to personalize treatment for cancer patients.
  • This patent award supports BriaCell's precision medicine approach and is part of the company's broader strategy to establish a strong international patent portfolio.
  • The technology aims to transform cancer care by personalizing immunotherapy for improved patient outcomes across multiple cancer indications.

Blood-Based Assay Detects Immunotherapy Response Up to 5 Months Earlier Than Standard Imaging

Precision Medicine
  • The RADIOHEAD study validated Guardant Reveal, a methylation-based liquid biopsy assay, for earlier detection of immunotherapy response in over 500 patients with advanced solid tumors across multiple cancer types.
  • Patients with an 80% or greater decrease in circulating tumor DNA showed a 75% lower risk of disease progression, while the assay identified treatment failure up to 5 months before standard imaging methods.
  • The tissue-free monitoring technology could enable oncologists to make faster treatment decisions, potentially sparing patients from ineffective therapies and improving clinical outcomes in immunotherapy management.

Relief Therapeutics to Merge with NeuroX in CHF 1 Billion Deal Creating AI-Driven Neurotherapeutics Platform

AIPrecision Medicine
  • Relief Therapeutics announced a binding agreement to merge with NeuroX Group, which recently acquired MindMaze's digital neurotherapeutics assets, in a transaction valued at CHF 1 billion for NeuroX and CHF 100 million for Relief.
  • The combined entity will create an AI-powered therapeutics platform integrating software-based neurorehabilitation with pharmacological treatments for neurological conditions including stroke, Parkinson's disease, and dementia.
  • Relief shareholders will own approximately 9% of the merged company, which will continue trading on the SIX Swiss Exchange with closing expected in Q4 2025.
  • NeuroX brings a clinically validated portfolio of digital neurotherapeutics backed by over USD 350 million in investment and partnerships with leading pharmaceutical companies across multiple clinical trials.

Avacta Completes Transition to Pure-Play Therapeutics with £2.2M Coris Sale

Precision MedicineOncology
  • Avacta Group has agreed to sell Coris Bioconcept SRL to 3B BlackBio Dx Ltd for £2.15 million upfront plus potential earn-outs of up to £615,000, completing its transformation into a pure-play therapeutics company.
  • The sale represents the final step in Avacta's strategic pivot away from diagnostics, following the earlier divestment of Launch Diagnostics in March 2025.
  • Proceeds will fund advancement of Avacta's preCISION platform for peptide drug conjugates targeting precision oncology treatments.
  • The transaction extends Avacta's cash runway into Q1 2026 and allows full focus on its tumor-targeting therapeutic pipeline powered by fibroblast activation protein technology.

KYAN Technologies' Ex Vivo Platform Demonstrates Clinical Utility in Relapsed/Refractory Non-Hodgkin Lymphoma

Precision Medicine
  • KYAN Technologies' Optim.AI™ platform achieved 74.5% accuracy in predicting clinical response in a prospective study of 117 relapsed/refractory non-Hodgkin lymphoma patients published in JCO Precision Oncology.
  • Patients treated with platform-guided combinations showed 59% objective response rates and three-fold improvement in progression-free survival compared to prior treatment lines.
  • The study represents the largest published cohort using an ex vivo functional precision medicine platform in lymphoma, demonstrating statistically significant survival benefits over salvage therapy (P = 0.0191).
  • The platform tests hundreds of clinically relevant drug treatments simultaneously on live tumor cells, providing oncologists with real-time, patient-specific treatment guidance.

Magnetically Steerable Drug Delivery Vesicles Show Promise for Precision Cancer Treatment

Precision MedicineTargeted Therapy
  • Researchers at the University of Illinois Urbana-Champaign have developed microscopic lipid vesicles containing magnetic particles that can be precisely steered to target locations using magnetic fields.
  • The system combines magnetic steering with light-triggered drug release, creating a comprehensive prototype for precision drug delivery that could significantly advance cancer treatment.
  • The lipid vesicles are designed to interact only with specific cell types, offering advantages for targeted cancer therapy while utilizing existing MRI technology for navigation.
  • The team is now preparing for in vitro studies using real drugs in microfluidic systems that simulate biological environments.

IDEAYA Biosciences to Present Phase 2 Darovasertib Data for Uveal Melanoma at ESMO 2025

Precision MedicineOncology
  • IDEAYA Biosciences will present Phase 2 clinical data on neoadjuvant darovasertib in primary uveal melanoma at the 2025 ESMO meeting in Berlin.
  • The presentation will include data from over 90 patients across both plaque brachytherapy and enucleation-eligible cohorts, focusing on enucleation prevention and vision preservation.
  • Darovasertib has received FDA Breakthrough Therapy Designation for neoadjuvant uveal melanoma in subjects requiring enucleation.
  • The company has initiated a multi-site, global randomized Phase 3 neoadjuvant registrational trial (OptimUM-10) in primary uveal melanoma in Q3 2025.

(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma

NCT05907954RecruitingPhase 2
IDEAYA Biosciences
Posted 7/3/2023

Neoadjuvant Darovasertib in Primary Uveal Melanoma

NCT07015190RecruitingPhase 3
IDEAYA Biosciences
Posted 10/1/2025

ASTRA Therapeutics Secures CHF 7.75 Million to Develop Novel Anti-Parasitic Drugs for Veterinary Medicine

Precision Medicine
  • ASTRA Therapeutics raised CHF 7.75 million in seed funding led by MIG Capital and Digitalis Ventures to advance its proprietary ParaX® platform for developing precision anti-parasitic drugs.
  • The Swiss biotech company targets the growing veterinary parasiticide market worth over $10 billion, addressing critical drug resistance issues where up to 98% of heartworm cases resist standard therapies in some regions.
  • ASTRA's pipeline includes over 15 patentable chemical classes of Parabulins® targeting tubulin in parasites, with initial proof-of-concept demonstrated for treating coccidia in farm animals and heartworm in pets.

Flatiron Health Triples Global Oncology Research Network, Expanding Real-World Data Access Across Three Countries

AIPrecision Medicine
  • Flatiron Health's international oncology research network has tripled in size over the past year, now encompassing more than 30 partnerships across the UK, Germany, and Japan.
  • The expansion brings Flatiron's total patient database above 5 million records, with new partnerships including major academic medical centers and national cancer centers in each country.
  • The company established Flatiron FORUM, a global consortium addressing data transportability challenges to support multinational cancer research and regulatory decisions.
  • Seven research studies using multinational real-world data have been completed within the past two years, demonstrating the platform's capability for cross-country cohort analyses.

Inotrem's Precision Medicine Strategy Shows Breakthrough Results for Septic Shock Treatment with Nangibotide

Precision Medicine
  • Inotrem published breakthrough precision medicine strategy for nangibotide in Intensive Care Medicine, demonstrating significant clinical improvements in septic shock patients with elevated sTREM-1 biomarker levels.
  • The study showed statistically significant organ function improvement (p=0.007) and increased shock reversal rates (+22.2%, p=0.006) in biomarker-positive patients who received nangibotide versus placebo.
  • This mechanism-based approach has regulatory approval from FDA, EMA, and PMDA, representing a new paradigm for drug development in intensive care medicine.
  • The precision medicine strategy addresses a critical unmet need in septic shock, which affects over 1.1 million people annually in the US and five main EU countries with mortality rates up to 40%.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.